DMAC vs RMT Comparison

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Royce Micro-Cap Trust Inc is a diversified closed-end investment company. The company is engaged in investing in micro-cap securities. It invests in the consumer discretionary sector including auto components, automobiles, diversified consumer services, hotels, restaurants and leisure, household durables, internet and catalog retail, leisure products, media, multiline retail, textiles, apparels, and luxury goods, Consumer staples sector including beverages, food, and staples retailing, food products, and personal products, Energy sector including energy equipment and services, and oil, gas, and consumable fuels. The company also invests in other sectors including healthcare, financials, industrials, IT, telecommunications, and materials.